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Nucleoside phosphoramidates
Compounds containing the phosphoramidate functionality have a range of biological activities
including acting as anticancer and cardioprotective agents. As phosphoric and carboxylic
equivalents, phosphoramidates have been evaluated as analogues of nucleosides and
oligonucleotides. Only a limited number of nucleoside phosphoramidates have been prepared
and evaluated for antiviral activity. A combinatorial approach was undertaken employing
screening of biologically relevant libraries for their ability to modulate biological pathways,
with or without regard to specific molecular targets. This strategy is appropriate in the context
of antiviral lead discovery, simultaneously identifying leads with the potential discovery of
novel molecular targets (Parallel solid-phase synthesis of nucleoside phosphoramidate libraries,
P.I. Radhakrishnan et. al., Bioorg. Med. Chem. Lett., 11, (2001), 2057-2060).
A library of 600 single phosphoramidates was synthesised on solid phase. Antiviral evaluation
of this library against hepatitis B virus in cell based assays helped validate the biological
relevance of the library with respect to its ability to cross cell membranes, its metabolic
stability and its antiviral activity. Several potent compounds were obtained from this library,
but only preliminary activity data was presented for the library in this publication. Further lead
optimisation is in progress by the authors to optimise the potency of this potentially new class
of nucleoside phosphoramidate compounds.
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Nonpeptide RGD mimetics
Integrins are a family of heterodimeric transmembrane cell surface receptors that are involved
in cell-cell and cell-matrix adhesion processes. More than 20 different integrin receptors have
been identified consisting of various combinations of at least 17 α- and 9 β-subunits.
Previously, integrins of the β3-subfamily have been the focus of drug discovery research;
attention being focussed towards the platelet integrin αIIbβ3. More recently the vitronectin
receptor αVβ3, expressed on almost all cells originating from the mesenchyme, has received
attention. This receptor represents a therapeutic target due to its important role in pathologies
as diverse as osteoporosis, restenosis following angioplasty, acute renal failure, ocular
diseases, tumour-induced angiogenesis and metastasis formation. The tripeptide sequence
RGD (Arg-Gly-Asp) is a common cell-recognition motif which is part of integrin binding
ligands such as fibronectin, fibrogen and vitronectin. The RGD sequence has been used as a
lead for developing different integrin antagonists and in particular recently, development of
selective nonpeptide αVβ3 integrin antagonists. Because of enhanced metabolic stability,
bioavailability and biological absorption of aza-amino acid containing peptides, a library of low
molecular weight RGD mimetics containing the aza-glycine has been undertaken (Solid phase
synthesis of a nonpeptide RGD mimetic library: New selective αVβ3 integrin antagonists, H.
Kessler et. al., J. Med. Chem., 44, (2001), 1938-1950).
A library of 37 single compounds was synthesised on a trityl chloride polystyrol (TCP) resin
(PepChem). Screening assays were performed by measuring the effect of RGD mimetics on
the interaction between immobilised integrin receptors and biotinylated soluble ligands. The
ability of RGD mimetics to inhibit the binding of vitronectin and fibrinogen to the isolated,
immobilised αVβ3 and αIIbβ3 receptors was compared to that of the standard peptides
GRGDSPK and c(RGDfV). One of the most active compounds obtained was (i) which gave
an IC50 of 0.1 nM against αVβ3 and >50000-fold selectivity over the platelet receptor αIIbβ3.
This work has provided potent and selective RGD mimetics with promising properties for
further pharmacokinetic investigations.
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